Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

77265

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.
	tabling member printed	The Countess of Mar
	uin	HL999
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p> answering member printed Earl Howe question first answered 24/07/2014 12:32:59 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

77264

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.
	tabling member printed	The Countess of Mar
	uin	HL998
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> answering member printed Earl Howe question first answered 24/07/2014 12:31:17 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

76631

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what they are doing to promote organ transplants.
	tabling member printed	Lord Bourne of Aberystwyth
	uin	HL973
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>The six years between April 2008 and April 2014 have seen a strengthening of the donation programme; increasing donation rates by 63% and transplant rates by 47%. The number of people registering for organ donation has increased by over 3 million since 2010 to over 20 million.</p><p> </p><p>A new seven year United Kingdom-wide organ donation and transplantation strategy <em>Taking Organ Transplantation to 2020: A UK strategy</em>, was published by NHS Blood and Transplant (NHSBT) in July 2013. The strategy sets out proposed action to increase consent rates, optimise donation and increase transplants.</p><p> </p><p>NHSBT continues to raise the profile of organ donation through a number of other ways. For example, people can join the Organ Donor Register online, through Facebook, by phone, post, registering with a general practitioner, a Boots pharmacy loyalty card or when applying for a passport. More people from Black, Asian and Minority Ethnic communities are needed to register on the Organ Donor Register and the recently launched Peer Educator Project, sponsored by the Department, training peer educators from the Pakistani Muslim community in Birmingham, is an example of action in this area. The Parliamentary Under-Secretary of State for Public Health (Jane Ellison) wrote to all Members during the National Transplant Week to raise the profile and benefits of organ donation and transplantation. The British Kidney Patient Association and NHS Blood and Transplant also held a reception in Parliament.</p><p> </p> answering member printed Earl Howe question first answered 23/07/2014 14:20:53 answering member 2000 label Biography information for Earl Howe
	tabling member	4282 label Biography information for Lord Bourne of Aberystwyth

76626

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Meningitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the timetable for the procurement and introduction of the meningitis B vaccine.
	tabling member printed	Baroness Corston
	uin	HL968
	answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>We are committed to introducing this vaccine as soon as practicable, in line with the Joint Committee on Vaccination and Immunisation’s recommendation, subject to the manufacturer offering the vaccine at a cost-effective price.</p> answering member printed Earl Howe question first answered 23/07/2014 12:36:57 answering member 2000 label Biography information for Earl Howe
	tabling member	215 label Biography information for Baroness Corston

228977

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Orphan Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to ensure that any decision around ultra-orphan drugs will be referred to the National Institute for Health and Care Excellence Highly Specialised Technologies Evaluation Committee.
	tabling member printed	Baroness Masham of Ilton
	uin	HL5942
	answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>We have referred a number of high cost, low volume technologies to the National Institute for Health and Care Excellence (NICE) for evaluation under its highly specialised technologies work programme. We will continue to do so for technologies that meet the specified criteria and where a NICE evaluation would add value. Further information about the process by which topics are selected for referral to NICE’s highly specialised technologies work programme is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/about/what-we-do/our-programmes/topic-selection" target="_blank">www.nice.org.uk/about/what-we-do/our-programmes/topic-selection</a></p><p> </p> answering member printed Earl Howe question first answered 25/03/2015 13:29:03 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

228976

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmacy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what will be the position of patients, previously served by a dispensing doctor practice, who live within 1.6 km of a pharmacy that closes, but still retains its licence, as a result of the closure of the Essential Small Pharmacies Scheme on 1 April 2015.
	tabling member printed	The Countess of Mar
	uin	HL5941
	answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The ending of the essential small pharmacy local pharmaceutical services scheme on 31 March 2015 does not require such pharmacies to close. That is a decision for the individual contractor concerned. They may decide to return to the main National Health Service pharmaceutical list and come under the terms of the national community pharmacy contractual framework. Alternatively, they can decide to submit a proposal to NHS England to provide local pharmaceutical services. NHS England is working with individual providers of essential small pharmacies to ensure people in affected communities can continue to access appropriate NHS pharmaceutical services. However, if an essential small pharmacy – or any other type of pharmacy - did decide to close, it would no longer be able to provide NHS pharmaceutical services.</p><p> </p><p> </p><p> </p><p>Patients can at any time request in writing that a doctor provides them with NHS pharmaceutical services. Applications should be made via the doctor to the appropriate NHS England office. To be eligible to receive dispensing services from a doctor, a patient must meet certain criteria, such as having serious difficulty obtaining services from a pharmacy or the patient lives in a designated rural area, more than 1.6 kilometres from the nearest pharmacy. These criteria are set out in Regulation 48 of the National Health Services (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 – SI 2013/349. A patient must also be on the doctor’s patient list, or the patient list of the practice at which the doctor provides or performs primary medical services, and the practice must be authorised by NHS England to provide NHS dispensing services.</p><p> </p> answering member printed Earl Howe question first answered 25/03/2015 16:21:09 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

228968

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Alcoholic Drinks: Excise Duties
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what were the dates of meetings ministers and officials from the Department of Health had with public health representatives to discuss the health impacts of potential cuts in alcohol duty between 1 November 2014 and 17 March 2015.
	tabling member printed	Lord Avebury
	uin	HL5933
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Ministers and officials in the alcohol policy team meet with public health representatives and experts on a regular basis in the course of their normal activities. Discussions on the general evidence base for the impacts of changes in alcohol duty may have been raised during these meetings. There have been no discussions on specific changes in alcohol duty.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 13:28:45 answering member 2000 label Biography information for Earl Howe
	tabling member	1665 label Biography information for Lord Avebury

228967

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Alcoholic Drinks
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what were the dates of meetings ministers and officials from the Department of Health had with (1) the Portman Group, (2) Drinkaware, (3) Diageo, (4) the Wine and Spirits Trade Association, (5) the British Beer and Pub Association, and (6) SABMiller, between 1 November 2014 and 17 March 2015.
	tabling member printed	Lord Avebury
	uin	HL5932
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Dates of meetings attended by the Parliamentary Under Secretary of State for Public Health and officials from the Department:</p><p> </p><p> </p><p> </p><p>- 5 November 2014 – Responsibility Deal alcohol network meeting, attendance included the Portman Group, Diageo, the Wine and Spirits Trade Association, the British Beer and Pub Association and SABMiller;</p><p> </p><p>- 18 November 2014 – Responsibility Deal Plenary Group meeting, attendance included the Portman Group; and</p><p> </p><p>- 3 March 2015 – The All-Party Parliamentary Beer Group reception promoting lower alcohol beers and wines. Attendance included Portman Group, the Wine and Spirits Trade Association, the British Beer and Pub Association and SABMiller.</p><p> </p><p> </p><p> </p><p>Details of meetings held by Ministers and the Permanent Secretary with external organisations are also published quarterly in arrears and can be found at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/collections/ministerial-gifts-hospitality-overseas-travel-and-meetings" target="_blank">https://www.gov.uk/government/collections/ministerial-gifts-hospitality-overseas-travel-and-meetings</a></p><p> </p><p> </p><p> </p><p>Dates of meetings attended by officials from the Department only:</p><p> </p><p> </p><p> </p><p>- 14 November 2014 – Meeting with industry on the EU alcohol strategy, attendance included the Wine and Spirits Trade Association, the British Beer and Pub Association and the Portman Group;</p><p> </p><p>- 4 December 2014 – Drinkaware medical panel meeting;</p><p> </p><p>- 21 January 2015 – Meeting with the Portman Group;</p><p> </p><p>- 3 February 2015 – Drinkaware Board meeting;</p><p> </p><p>- 5 February 2015 – Meeting with the Wine and Spirits Trade Association;</p><p> </p><p>- 16 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 17 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 19 February 2015 – Meeting with SABMiller;</p><p> </p><p>- 25 February 2015 – Meeting with the Portman Group;</p><p> </p><p>- 26 February 2015 – Meeting with SABMiller; and</p><p> </p><p>- 26 February 2015 – Meeting with Drinkaware.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:59:13 answering member 2000 label Biography information for Earl Howe
	tabling member	1665 label Biography information for Lord Avebury

228955

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Muscular Dystrophy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to ensure that the National Health Service supports people with muscular dystrophy.
	tabling member printed	Lord Taylor of Warwick
	uin	HL5920
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>Through the Mandate we have asked NHS England to make measurable progress towards making our health service among the best in Europe at supporting people with long-term conditions such as muscular dystrophy, to live healthily and independently, with much better control over the care they receive.</p><p> </p><p> </p><p> </p><p>NHS England commissions specialised neurological services at a national level, including for patients with muscular dystrophy. The neurosciences service specifications set out that patients with neuromuscular conditions, such as muscular dystrophy should have access to a multidisciplinary team (MDT) who will assess, diagnose and provide support. The MDT team will include neuromuscular consultants, neuromuscular physiotherapists, specialist nurses, occupational therapists, speech and language therapists and other care professionals. One of the key service outcomes of the specification is that all patients with long-term neurological conditions have an individualised care plan.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:58:00 answering member 2000 label Biography information for Earl Howe
	tabling member	1796 label Biography information for Lord Taylor of Warwick

228954

	registered interest
	date	23/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Meningitis: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what are the reasons for delays in introducing a vaccine against meningitis B.
	tabling member printed	Lord Taylor of Warwick
	uin	HL5919
	answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The introduction of the meningococcal B vaccine, Bexsero, depends on the outcome of negotiations with the manufacturer for supply at a cost-effective price, as recommended by the Joint Committee on Vaccination and Immunisation. We aim to conclude these negotiations as soon as possible.</p><p> </p> answering member printed Earl Howe question first answered 26/03/2015 12:56:00 answering member 2000 label Biography information for Earl Howe
	tabling member	1796 label Biography information for Lord Taylor of Warwick